European Patent Office

T 1258/16 (Abiraterone prednisone combination for treatment of prostate cancer/JANSSEN) of 06.02.2020

European Case Law Identifier
ECLI:EP:BA:2020:T125816.20200206
Date of decision
6 February 2020
Case number
T 1258/16
Petition for review of
-
Application number
07837326.3
Language of proceedings
English
Distribution
No distribution (D)
OJ versions
No OJ links found
Other decisions for this case
-
Abstracts for this decision
-
Application title
Compositions for treating cancer
Applicant name
Janssen Oncology, Inc.
Opponent name
Alfred E. Tiefenbacher (GmbH & Co. KG)
Helm AG
Laboratorios Léon Farma, S.A.
STADA Arzneimittel AG
Hetero Drugs Ltd.
CABINET LAVOIX
Synthon B.V./Genthon B.V.
Galenicum Health S.L.
Teva Pharmaceutical Industries LTD.
Maiwald Patent- und Rechtsanwaltsgesellschaft mbH
Generics [UK] Limited
Actavis Group PTC ehf
Gallafent, Alison
Patentanwälte Isenbruck Bösl Hörschler PartG mbB
Zentiva k.s.
Board
3.3.01
Headnote
-
Relevant legal provisions
European Patent Convention Art 113(2)
Keywords
Basis of decision - text or agreement to text withdrawn by patent proprietor
Catchword
-
Citing cases
T 0777/15

Order

For these reasons it is decided that:

The appeal proceedings are terminated.